Latest News Archive
Please select Category, Year, and then Month to display items
29 March 2021
|
Story Lacea Loader
![]()
1. Its support of and confidence in the leadership of the Rector and Vice-Chancellor of the UFS, Prof Francis Petersen and his team, and duly recognises the efforts and results achieved at the University during the challenges posed by the COVID-19 pandemic, as well as the current nationwide student protest on the payment of student debt.
2. In this context, the Council also distances itself and deplores the statements made by the leadership of the
Institutional Student Representative Council (ISRC), on national television on Monday 15 March 2021, as it pertained to the demand for the immediate resignation of the Rector and Vice-Chancellor, and the statements pertaining to the Chancellor, Prof Bonang Mohale, and Chairperson of the Council, Dr Willem Louw. The Council notes that Mr Katleho Lechoo, President of the ISRC subsequently retracted the utterances.
3. The Council strongly affirms its confidence in the relationship between the leadership of the UFS and the ISRC and expresses its appreciation for the University leadership’s commitment to continuously engage with students about matters of concern to them. The Council furthermore encourages positive and constructive engagement by the ISRC with the University leadership, as this contributes to shared-understanding of the challenges faced by the South African higher education sector and the governance of the UFS.
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004